Key facts
- This page summarizes Sukhtian Ghiath M.'s Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
- 7 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2026, 21:30.
Sukhtian Ghiath M. - 28 May 2026 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- OTLK
- Reported as of
- 28 May 2026
- Net transaction value
- +$5,000,000
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2026, 21:30:12 UTC
- Prior SEC filing
- 28 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ghiath M. Sukhtian, By: Lawrence Kenyon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sukhtian Ghiath M. filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 01 Jun 2026.
Change
- Previous filing in this sequence was filed on 28 May 2025.
- Current net transaction value: +$5,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (2)
CIK 0001717441
Primary reporting owner
Sukhtian Ghiath M.
- Relationship
- Director, 10%+ Owner
- Address
- 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN, JORDAN
- Signature
- /s/ Ghiath M. Sukhtian, By: Lawrence Kenyon, Attorney-in-Fact
- Signature date
- 01 Jun 2026
CIK 0001804598
GMS Ventures & Investments
- Relationship
- Director, 10%+ Owner
- Address
- C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN, CAYMAN ISLANDS
- Signature
- /s/ GMS Ventures and Investments, By: Lawrence Kenyon, Attorney-in-Fact
- Signature date
- 01 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OTLK
transaction
Common Stock
Purchase
- Transaction value
- $5,000,000
- Shares
- +8,539,709
- Change %
- +63%
- Price
- $0.5855
- Shares after
- 22,092,068
- Date
- 28 May 2026
- Ownership
- See footnote
- Footnotes
- F1, F2, F3
OTLK
transaction
Common Stock
Purchase
- Transaction value
- $5,000,000
- Shares
- +8,539,709
- Change %
- +63%
- Price
- $0.5855
- Shares after
- 22,092,068
- Date
- 28 May 2026
- Ownership
- See footnote
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OTLK
transaction
Derivative
Warrants (right to buy)
Expiration (or cancellation) of long derivative position with value received
- Transaction value
- Shares
- -3,458,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $2.26
- Footnotes
- F2, F3, F4
OTLK
transaction
Derivative
Warrants (right to buy)
Expiration (or cancellation) of long derivative position with value received
- Transaction value
- Shares
- -3,458,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $2.26
- Footnotes
- F2, F3, F4
OTLK
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +3,458,571
- Change %
- Price
- Shares after
- 3,458,571
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $0.5855
- Footnotes
- F2, F3, F4
OTLK
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +3,458,571
- Change %
- Price
- Shares after
- 3,458,571
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $0.5855
- Footnotes
- F2, F3, F4
OTLK
transaction
Derivative
Warrants (right to buy)
Expiration (or cancellation) of long derivative position with value received
- Transaction value
- Shares
- -3,458,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $2.26
- Footnotes
- F2, F3, F5
OTLK
transaction
Derivative
Warrants (right to buy)
Expiration (or cancellation) of long derivative position with value received
- Transaction value
- Shares
- -3,458,571
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $2.26
- Footnotes
- F2, F3, F5
OTLK
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +3,458,571
- Change %
- Price
- Shares after
- 3,458,571
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $0.5855
- Footnotes
- F2, F3, F5
OTLK
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +3,458,571
- Change %
- Price
- Shares after
- 3,458,571
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,458,571
- Exercise price
- $0.5855
- Footnotes
- F2, F3, F5
OTLK
transaction
Derivative
Warrants (right to buy)
Expiration (or cancellation) of long derivative position with value received
- Transaction value
- Shares
- -8,571,428
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,571,428
- Exercise price
- $1.40
- Footnotes
- F2, F3, F6
OTLK
transaction
Derivative
Warrants (right to buy)
Expiration (or cancellation) of long derivative position with value received
- Transaction value
- Shares
- -8,571,428
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,571,428
- Exercise price
- $1.40
- Footnotes
- F2, F3, F6
OTLK
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +8,571,428
- Change %
- Price
- Shares after
- 8,571,428
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,571,428
- Exercise price
- $0.5855
- Footnotes
- F2, F3, F6
OTLK
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +8,571,428
- Change %
- Price
- Shares after
- 8,571,428
- Date
- 28 May 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,571,428
- Exercise price
- $0.5855
- Footnotes
- F2, F3, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
On May 28, 2026, GMS Ventures and Investments ("GMS Ventures") entered into a securities purchase agreement with Outlook Therapeutics, Inc. (the "Issuer") pursuant to which the Issuer agreed to issue and sell 8,539,709 shares of the Issuer's common stock at $0.5855 per share in a registered direct offering for a total purchase price of approximately $5.0 million.
Footnote F2
These securities are held of record by GMS Ventures. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization.
Footnote F3
By virtue of the relationships described above in Footnote 2, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Footnote F4
The transactions reported in Table II above involved the amendment of the outstanding Tranche A warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.
Footnote F5
The transactions reported in Table II above involved the amendment of the outstanding Tranche B warrants issued on January 16, 2025 to reduce the exercise price from $2.26 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.
Footnote F6
The transactions reported in Table II above involved the amendment of the outstanding warrants issued on May 27, 2025 to reduce the exercise price from $1.40 per share to $0.5855 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.